DocGo Inc. DCGO
- Market cap
- $33.6M
- P/E
- 0.0×
Follow DCGO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.95 | 7.14 | 4.96 | 4.80 | 2.75 | 0.86 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 10.51 | 11.86 | 11.41 | 10.82 | 5.61 | 5.68 |
High Price
|
|||
| — | — | — | — | 4 | 2,924 | 3,252 | 4,164 | 4,407 | 3,568 |
Employees
|
|||
| — | — | — | — | 24 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 94 | 319 | 441 | 624 | 617 | 322 |
Revenue
|
|||
| — | — | — | — | 33.32% | 34.43% | 35.12% | 31.30% | 34.64% | 30.65% |
Gross Margin
|
|||
| — | — | — | — | (15) | 20 | 23 | 16 | 28 | (187) |
EBT
|
|||
| — | — | — | — | (15.55%) | 6.21% | 5.17% | 2.61% | 4.50% | (58.19%) |
EBT Margin
|
|||
| — | 0 | — | — | (15) | 19 | 31 | 10 | 13 | (196) |
Net Income
|
|||
| — | — | — | — | 6 | 7 | 13 | 16 | 16 | 74 |
Depreciation
|
|||
| — | — | — | — | 1.61 | 3.97 | 4.35 | 6.03 | 6.02 | 3.25 |
Revenue/Sh
|
|||
| — | — | — | — | (0.25) | 0.30 | 0.34 | 0.07 | 0.20 | (1.84) |
Earnings/Sh
|
|||
| — | — | — | — | (0.18) | (0.02) | 0.29 | (0.62) | 0.68 | 0.35 |
Cash Flow/Sh
|
|||
| — | — | — | — | (0.10) | (0.08) | (0.05) | (0.09) | (0.05) | (0.07) |
Capex/Sh
|
|||
| — | — | — | — | (0.29) | (0.11) | 0.23 | (0.71) | 0.63 | 0.27 |
Free CF/Sh
|
|||
| — | — | — | — | 1.15 | 2.83 | 2.76 | 2.95 | 3.08 | 1.27 |
Book Value/Sh
|
|||
| — | — | — | — | 58 | 80 | 101 | 104 | 102 | 99 |
Shares
|
|||
| — | — | — | — | 0.00 | 7.10 | 20.53 | 73.86 | 22.32 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 2.36 | 1.70 | 0.86 | 0.70 | 0.27 |
PS Ratio
|
|||
| — | — | — | — | 2.18 | 3.31 | 2.68 | 1.75 | 1.38 | 0.69 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | 1.81 | 1.34 | 0.76 | 0.56 | 0.11 |
EV/Sales
|
|||
| — | — | — | — | 0.00 | (67.19) | 25.33 | (6.47) | 5.32 | 1.34 |
EV/FCF
|
|||
| — | — | — | — | (11) | (2) | 29 | (64) | 70 | 34 |
Op' Cash Flow
|
|||
| — | — | — | — | (6) | (7) | (5) | (9) | (5) | (7) |
Capex
|
|||
| — | — | — | — | (17) | (9) | 23 | (74) | 65 | 27 |
FCF
|
|||
| — | — | — | — | 35 | 198 | 171 | 169 | 183 | 85 |
Working Cap'
|
|||
| — | — | — | — | 1 | 1 | 1 | 0 | 0 | 0 |
Total Debt
|
|||
| — | — | — | — | (32) | (174) | (156) | (59) | (89) | (51) |
Net Debt
|
|||
| — | — | — | — | 67 | 227 | 279 | 305 | 315 | 126 |
Sh' Equity
|
|||
| — | — | — | — | (28.67%) | 11.59% | 9.84% | 1.55% | 4.23% | (54.23%) |
ROA
|
|||
| — | — | — | — | (26.26%) | 18.17% | 11.11% | 3.83% | 7.94% | (148.29%) |
ROIC
|
|||
| — | — | — | — | (10.46%) | 16.15% | 13.67% | 2.35% | 6.45% | (82.71%) |
ROE
|
|||
DocGo Inc. peers in Medical Care Facilities
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CCEL Cryo-Cell International Inc. | $32.5M | 0.0× | Compare |
| BTMD biote Corp. | $44.2M | 7.8× | Compare |
| PIII P3 Health Partners Inc. | $51.2M | 0.0× | Compare |
| PAIYY Aesthetic Medical International Hldngs Group Ltd Sponsored ADR | $15.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PARK Park Dental Partners, Inc. | $93.3M | 0.0× | Compare |
| CCM Concord Medical Services Holdings Limited | $10.0M | 0.0× | Compare |
| AMS American Shared Hospital Services | $9.7M | 0.0× | Compare |
| JYNT The Joint Corp. | $117.3M | 30.5× | Compare |
DocGo Inc. (DCGO) key facts
- DocGo Inc. (DCGO) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
- DocGo Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.2 million, down 47.7% from fiscal 2024.
- DocGo Inc. reported a net loss of $196.4 million, or a loss of $1.84 per share, for fiscal 2025.
- As of September 25, 2026, DCGO traded at $0.34, a market capitalization of $33.6 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.1× sales.
- Return on equity was −82.7% and debt-to-equity 0.00.
DocGo Inc. (DCGO) Latest News
23 Sep
DocGo announced a webinar on Sept. 29 at 11:00 a.m. ET featuring CEO Lee Bienstock and Hicuity Health executives to outline the vision and details of DocGo's pending acquisition of Hicuity Health, a provider of tele-ICU, virtual nursing, telemetry monitoring and other virtual care services. The session will be webcast via Viavid and on DocGo's IR site, with presentation materials posted beforehand. DocGo touts its platform of mobile health, remote patient monitoring, ambulance services and a 50-state virtual care network, and says the deal could reshape healthcare delivery by bridging physical and virtual care. Contacts. Pending acquisition could significantly expand DocGo's tele-ICU and virtual care footprint, potentially altering growth trajectory and investor sentiment.
18 Aug
DocGo Inc achieved record volumes in Q2 2026 alongside strategic Hicuity initiatives during its earnings call. Record volumes and strategic initiatives position DocGo for substantial growth in competitive healthcare logistics market.
DocGo Inc. conducted its Q2 2026 earnings call, covering financial results and operational updates. Quarterly earnings calls deliver performance data and guidance that can shift near-term stock sentiment and valuations.
DocGo shares declined sharply after the company missed earnings expectations and projected wider losses ahead. Earnings miss combined with wider loss guidance will weigh on near-term financial results and stock sentiment.
17 Aug
DocGo Inc. held its Q2 earnings call covering revenue figures, contract wins, operational metrics, and forward guidance on growth initiatives and market expansion. Earnings results and guidance typically produce moderate short-term effects on valuation and sentiment without guaranteeing structural shifts.
DocGo Inc. (DCGO) surpassed Q2 earnings estimates. Q2 earnings beat for DocGo Inc. may lift near-term investor sentiment without altering long-term trajectory.
DocGo Inc. (DCGO) announced financial results for the second quarter of 2026. Quarterly results release supplies updated financial metrics that can shift near-term investor views and valuation.
16 May
DocGo Inc. aims for profitability by pivoting to mobile health services and medical transport. Major strategic pivot to mobile health and transport targets profitability and could significantly alter company trajectory.
Optimism in transport for DocGo clashes with lowered valuation targets, shifting the company's narrative and likely pressuring its stock performance and investor outlook. Lowered valuation targets create moderate downward pressure on DocGo's market trajectory despite transport sector optimism.
14 May
Analysts value DocGo Inc. (NASDAQ:DCGO) at US$1.87 following its latest results. Analyst fair value of $1.87 after results highlights potential concerns over financial performance and market sentiment.
12 May
DocGo Inc. released its Q1 2026 earnings call summary, covering financial results, operational updates, and forward guidance for the mobile healthcare provider. Quarterly earnings data and guidance can shift near-term stock sentiment and valuation but rarely transform long-term strategy.
DocGo Inc. (DCGO) reported strong revenue growth in Q1 2026 earnings call highlights, despite ongoing operational challenges. Strong revenue growth positively influences financial performance, balanced by operational challenges limiting broader trajectory shifts.
11 May
DocGo Inc. (DCGO) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights detail financial performance and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.
DocGo Inc. (DCGO) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, management commentary, and forward-looking guidance. Q1 2026 earnings transcript discloses financial performance, strategic initiatives, and guidance that significantly shape investor expectations and stock trajectory.
DocGo Inc. (DCGO) announced first quarter 2026 financial results. Quarterly earnings announcements directly influence financial performance, stock valuation, and investor sentiment for DocGo.
DocGo Inc. (DCGO) reported a Q1 net loss but beat revenue estimates. Q1 loss despite revenue beat moderately influences financial performance and market sentiment without fundamentally changing trajectory.
7 Apr
DocGo (DCGO) shifts strategy to emphasize transportation services as prior growth targets fall short, aiming to rewrite its narrative with renewed focus on core transport operations. Strategic pivot to transport amid missed targets signals major shift in operations and investor outlook.
16 Mar
DocGo Inc. (DCGO) Q4 2025 earnings call highlights revenue surpassing expectations amid ongoing growth and strategic developments. Revenue beating expectations in Q4 2025 signals strong financial health and potential for enhanced investor sentiment and stock performance.
DocGo Inc. Q4 2025 earnings call summary covers financial results, operational highlights, strategic updates, and forward guidance. Q4 2025 earnings call summary discloses key financials and guidance that could significantly sway investor sentiment and stock performance.
DocGo Inc. (DCGO) reported Q4 revenue of $186.8 million, up 43% year-over-year, with full-year revenue reaching $639.6 million. The company achieved positive adjusted EBITDA of $5.4 million in Q4 and $15.7 million for the year. Key highlights include expansion of mobile health services, new contracts with Uber Health and national health plans, and 2024 guidance projecting revenue of $850-900 million and adjusted EBITDA of $55-65 million. Strong Q4 revenue growth, profitability achievement, and ambitious 2024 guidance signal significant positive trajectory shifts for DCGO.
DocGo Inc. (DCGO) released Q4 2025 earnings call transcript detailing financial results, executive insights, and forward guidance. Q4 2025 earnings transcript discloses key financial metrics, strategic updates, and outlook directly impacting investor sentiment and market performance.
DocGo Inc. (DCGO) announced fourth quarter and full year 2025 financial results. Earnings announcements for Q4 and full year directly impact financial performance and investor sentiment.
DocGo Inc. (DCGO) reported a Q4 net loss but beat revenue estimates. Q4 loss despite revenue beat affects financial performance and investor sentiment moderately.
9 Mar
DocGo CEO at conference outlined 'Healthcare at Any Address' vision, targeting $280M-$300M revenue by 2026. CEO's revenue guidance of $280M-$300M by 2026 represents a major strategic growth target likely boosting investor sentiment.
27 Jan
DocGo Inc.'s SteadyMD has announced an immediate expansion of its clinical workforce to address the increasing demand for branded GLP-1 weight loss care. This move aims to enhance service delivery and meet the growing needs of patients seeking weight management solutions. The expansion of the clinical workforce is a significant strategic move that could enhance service capacity and market positioning in the growing weight loss sector.
11 Nov
DocGo Inc. (DCGO) reported a decline in revenue during Q3 2025, prompting discussions on strategic adjustments to address the downturn. The earnings call highlighted challenges faced by the company, including competitive pressures and market dynamics. Management outlined plans to enhance operational efficiency and explore new growth opportunities to stabilize financial performance moving forward. Revenue declines and strategic adjustments may moderately influence financial performance and market positioning.
10 Nov
DocGo Inc. reported its third quarter 2025 financial results, highlighting a revenue increase driven by expanded service offerings and strategic partnerships. The company achieved significant growth in patient transport services and telehealth solutions, contributing to improved profitability. Management expressed optimism about future growth prospects and outlined plans for further market expansion and innovation in healthcare delivery. The financial results indicate significant growth and strategic initiatives that could alter the company's trajectory and investor sentiment.
DocGo Inc. (DCGO) reported a loss for Q3 but exceeded revenue estimates. The company's financial performance showed resilience despite the loss, indicating potential for future growth. Investors may view the revenue beat positively, although the loss raises concerns about profitability. The revenue beat suggests moderate influence on market sentiment, but the reported loss limits the overall positive impact.
4 Nov
DocGo Inc. announced the upcoming launch of its Longitudinal Care Services for a major health plan in California, aiming to enhance patient care and streamline healthcare delivery. This initiative is expected to improve access to healthcare services and support the company's growth in the region. The launch of Longitudinal Care Services represents a significant strategic move that could enhance DocGo's market position and investor sentiment.
22 Oct
DocGo Inc. (DCGO) is highlighted as a promising penny stock for October 2025, with analysts noting its potential for growth in the healthcare sector. The company has been expanding its services and improving operational efficiencies, which may attract investor interest. Market trends indicate a favorable environment for healthcare-related stocks, further enhancing DocGo's prospects. Investors are encouraged to monitor the company's developments closely as it navigates this evolving landscape. Significant strategic moves and market trends in healthcare are likely to impact DocGo's future performance.